万珂周疗方案对多发性骨髓瘤疗效及安全性的Meta分析

A Meta-analysis on weekly bortezomib schedule for multiple myeloma

目的:评价万珂(硼替佐米)周疗方案与传统的一周2次疗法对多发性骨髓瘤患者的疗效及安全性。方法:应用国际Cochrane协作网的系统评价方法,经计算机检索,纳入万珂周疗方案治疗多发性骨髓瘤的随机对照试验,评价纳入研究的质量,并进行资料提取后,采用RevMan5.0软件进行Meta分析。结果:共纳入4篇文献,包括876例患者,万珂周疗方案治疗组与传统方案治疗的对照组反应率比较无统计学差异,但周围神经病变的发生率下降。结论:目前万珂周疗方案对多发性骨髓瘤的治疗有良好疗效,且周围神经病变的不良反应较传统方案小,但由于纳入研究样本量小且质量较低,上述结论尚需要高质量、大样本的随机双盲对照试验加以证实。

Objective ：To evaluate the curative effect and adverse effect of weekly bortezomib schedule and stand- ard twice -weekly schedule for patients with multiple myeloma. Methods： We used the systematic review method of The Cochrane Collaboration to collect randomized controlled trials （RCTs） of weekly bortezomib chemotherapy for multiple myeloma. Results： Five trials involving 876 patients were retrieved, The overall responsed rate between the treatment group and the control group was no statistically significance ; The incidence of peripheral neuropathy in the treatment group was lower. Conclusion： Multiple myeloma treated by weekly bortezomib schedule can produce a sim- ilar therapeutic effect as twice - weekly schedule, and reduce the adverse effects. But the included studies were low sample size, and low quality, more high - quality, large - sample size, randomized, double - blind, controlled trials are required.